发明名称 AZAINDOLES
摘要 The invention is directed to compositions containing physiologically active compounds of general formula (I):- wherein R 1 is aryl or heteroaryl; R 2 represents hydrogen, acyl, cyano, halo, lower alkenyl or lower alkyl optionally substituted by a substituent selected from cyano, heteroaryl, heterocycloalkyl, -Z 1 R 8 , -C(=O)-NY 3 Y 4 , -CO 2 R 8 , -NY 3 Y 4 , -N(R 6 )-C(=O)-R 7 , -N(R 6 )-C(=O)-NY 3 Y 4 , -N(R 6 )-C(=O)-OR 7 , -N(R 6 )-SO 2 -R 7 , -N(R 6 )-SO 2 -NY 3 Y 4 and one or more halogen atoms; R 3 represents hydrogen, aryl, cyano, halo, heteroaryl, lower alkyl, -C(=O)-OR 5 or -C(=O)-NY 3 Y; and X 1 represents CH, C-halo, C-CN, C-R 7 , C-NY 3 Y 4 , C-OH, C-Z 2 R 7 , C-C(=O)-OR 5 , C-C(=O)-NY 3 Y 4 , C-N(R 8 )-C(=O)-R 7 , C-SO 2 -NY 3 Y 4 , C-N(R 8 )-SO 2 -R 7 , C-alkenyl, C-alkynyl or C-NO 2 ; and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs, as well as to novel compounds within the scope of formula (I). Such compounds and compositions have valuable pharmaceutical properties, in particular the ability to inhibit protein kinases.
申请公布号 HRP20020547(A2) 申请公布日期 2005.10.31
申请号 HR2002P000547 申请日期 2002.06.21
申请人 AVENTIS PHARMA LIMITED 发明人 PAUL JOSEPH COX;TAHIR NADEEM MAJID;JUSTINE YEUN QUAI LAI;MORLEY ANDREW DAVID;SHELLEY AMENDOLA;STEPHANIE DEPRETS;CHRIS EDLIN
分类号 A61K31/437;A61K31/4985;A61K31/5377;A61P1/04;A61P3/10;A61P9/10;A61P9/14;A61P11/00;A61P11/02;A61P11/06;A61P17/06;A61P19/02;A61P19/06;A61P25/28;A61P27/14;A61P29/00;A61P35/00;A61P35/02;A61P37/02;A61P37/06;A61P37/08;A61P43/00;C07D471/04;C07D487/04;C07D519/00 主分类号 A61K31/437
代理机构 代理人
主权项
地址